Omega Fund Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Omega Fund Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,556	Closed	-$11.9M	–	12
2017 Q2	$11.9M	Sell	4,556 -28	-0.6%	-$72.2K	7.45%	4
2017 Q1	$13.8M	Hold	4,584	–	–	8.94%	5
2016 Q4	$6.83M	Hold	4,584	–	–	5.54%	5
2016 Q3	$8.08M	Hold	4,584	–	–	6.17%	5
2016 Q2	$8.59M	Hold	4,584	–	–	6.38%	5
2016 Q1	$10.3M	Hold	4,584	–	–	7.12%	5
2015 Q4	$11M	Hold	4,584	–	–	6.13%	5
2015 Q3	$10.9M	Buy	+4,584	New	+$12.2M	6.13%	5

Other funds holding NBRV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Omega Fund Management's NBRV Position: Q3 2017 in Review

Omega Fund Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2017, closing a stake of 4,556 shares — an estimated $11.9M sold.

Omega Fund Management first reported a position in NBRV in Q3 2015 and held it in 8 quarters. The position peaked at $13.8M in Q1 2017. 41 funds tracked by Wall St. Rank hold NBRV as of Q3 2017.

Omega Fund Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2017 after selling out during the quarter.
Omega Fund Management sold 4,556 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2017, an estimated $11.9M.
Omega Fund Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 8 quarters.
Omega Fund Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $13.8M in Q1 2017.
41 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2017.

Based on Omega Fund Management's 13F filing for Q3 2017, filed 3 Nov 2017.